219312-08-0

Basic information

• Product Name: Benzenamine, 4-chloro-2-methyl-3-nitro-
• CAS NO: 219312-08-0
• Molecular Formula: C7H7ClN2O2
• Molecular Weight: 186.598
• Mol File: 219312-08-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenamine, 4-chloro-2-methyl-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 4-chloro-2-methyl-3-nitro-(219312-08-0)
• EPA Substance Registry System: Benzenamine, 4-chloro-2-methyl-3-nitro-(219312-08-0)

Safety Data

• Hazardous Substances Data: 219312-08-0(Hazardous Substances Data)

Upstream product

• 606-20-2 2,6-dinitrotoluene 
• 7647-01-0 hydrogenchloride 
• 5805-95-8 2-hydroxylamino-6-nitrotoluene 
• 79913-56-7 3-chloro-2,6-dinitrotoluene 
• 10202-92-3 3-methyl-2,4-dinitroaniline 

Downstream Products

• 1080522-61-7 methyl 2-(4-(4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yloxy)-3-methoxyphenyl)acetate 
• 1080521-20-5 2-(4-(4-(2,4-dichlorophenylsulfonamido)-1H-indazol-5-yloxy)-3-methoxyphenyl)acetic acid 
• 1080522-62-8 methyl 2-(4-(4-(2,4-dichlorophenylsulfonamido)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yloxy)-3-methoxyphenyl)acetate 
• 4771-47-5 3-chloro-2-nitro-benzoic acid 
• 5367-26-0 3-chloro-2-nitrotoluene 

Relevant articles and documents

COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION

Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists

The present invention concerns novel compounds represented by the Formula:*(formula 02)* wherein: A is R1q(R3R60N)m(Z)(NR2)n; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2; n is 1 with the proviso that, when Z is C=O, m is 1; X is -NH-, -CH2-, or -OCH2-; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the proviso that, when R1 is H, m is 1; R2, R3, R60 are each independently H, lower alkyl, or phenyl; R4, R5, R6, and R7 are each independently hydrogen, lower alkyl, - CF 3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R2 and R7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or -CN,with the proviso that, when R7 is hydroxyl or lower alkylsulfonamido, then X is not -NH- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R1SO2NR2-), (R3R60NSO2NR2-), or (R3R60NCONR2-). The invention also includes the use of the above compounds, and compositions containing them, as alpha 1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.